Table 1

Characteristics of studies included

MethodsParticipantsInterventionsOutcome measuresNotes
Wilkens et al30RCT Double-blind Single centreOutpatients (N=250) Country—Norway Mean age 48.5, 48.4% female Inclusion criteria: Chronic LBP >6 months, MRI findings indicating degenerative lumbar OA, age >251500 mg glucosamine sulphate versus placebo for 6 monthsPrimary outcome: disability—RMDQ Secondary outcomes: pain at rest and during activity (11-point scale), quality of life (QOL): EQ-5D and EQ-VAS, global perception of effect (7 point scale) Adverse effectsSponsored by Pharma Nord
Tant et al31RCT Open-label Single centreOutpatients (N=36) Country—Belgium Mean age 64, 43.8% female Inclusion criteria: LBP >12 weeks with associated signs of lumbar arthrosis on radiography, pain score on VAS >3 mmConventional treatment (CT) (anti-inflammatory and physical therapy) plus glucosamine complex (containing equivalent: 1500 mg glucosamine, 200 mg of Ribes nigrum, 2000 mg methylsulfonylmethane and 100 mg colloidal silicon) for 12 weeks vs CT alonePrimary outcome: pain at rest on VAS
Secondary outcomes: lumbar stiffness on VAS, 2 QOL questionnaires—ODI and RMDQ, global assessment of treatment (satisfied or not) Adverse effects
Sponsored by Pierre Fabre Sante
Leffler et al32RCT (cross-over) Double-blind Single centreOutpatients (N=34, 23 back patients) Country—USA Mean age 43.5 100% male Inclusion Criteria: chronic knee or low back pain on most days for at least 3 months and radiographic evidence of degenerative joint disease16 weeks (8 weeks each arm). 1500 mg glucosamine hydrochloride, 1200 mg chondroitin sulphate, 228 g manganese ascorbate vs placeboPain (VAS scores), Function: Lequesne Index ( knee), RMDQ (back), patient assessment of handicap, physician assessment of severity and physical examination scoresPatients from US Navy diving and special warfare community
Mixed population of knee and back pain (21—knee OA, 23—spinal degenerative joint disease
Data separated by site for analysis
Sponsored by Nutramax